BioFIND Schedule of Activities						
PARKINSON DISEASE (PD) SUBJECTS						
Visit Description	**Level #**	**Baseline/V01 Day 0**	**V02 Day 14**	**Telephone Call T01[6]**	**FNL**	**Unscheduled Visit[5]**
Confidential Subject Identification Log		X				
Written Informed Consent		X				
Screening/Demographics	02	X				
Socio-Economics	04	X				
CTCC Unique ID	06	X				
Inclusion/Exclusion - PD	08	X				
PD Features	10	X				
Primary Diagnosis	12	X				
Medical History (General)	14	X				
Smoking and Alcohol Questionnaire	15	X				
Family History (PD)	16	X				
General Neurological Exam	18	X				
Vital Signs	20	X	X			X
Fasting Status	21	X	X			
Use of PD Medication	22	X	X			
MDS-UPDRS 1	24	X				
MDS-UPDRS 2	24	X				
MDS-UPDRS 3/Hoehn & Yahr	24	X	X[1]			
MDS-UPDRS 4	24	X				
Modified Schwab & England ADL	26	X				
Montreal Cognitive Assessment (MoCA)	30	X				
REM Sleep Disorder Questionnaire	32	X				
DNA Sample	34	X				
Laboratory Procedures	36	X[2]	X[4]			
Saliva and Urine Samples	37		X			
Clinical Labs	38	X[3]				
Lumbar Puncture	40		X			
Investigator Signature	42	X	X	X		X
Visit Status	44	X	X	X		X
Adverse Event Log	46		X	X		
Concomitant Medication Log	50	X	X	X		X
Adverse Event Follow-up Log[7]	54			X		
Conclusion of Study Participation	52				X	

1 MDS-UPDRS part 3 motor only
2 10ml plasma between 1-3 hours after meds
3 CBC, platelet count, PT/PTT
4 Laboratory procedures include PAXgene™ and plasma EDTA purple top
5 Assessments at the discretion of the Investigator and to be recorded in source document
6 Adverse events assessed by phone 7 - 10 days following LP
7Any AE ongoing at the 7 to 10 day reporting telephone visit should be followed until resolution or stabilization, but not more than 30 days from lumbar puncture.

BioFIND Schedule of Activities						
HEALTHY CONTROL (HC) SUBJECTS						
Visit Description	**Level #**	**Baseline/V01 Day 0**	**V02 Day 14**	**Telephone Call T01[6]**	**FNL**	**Unscheduled Visit[5]**
Confidential Subject Identification Log		X				
Written Informed Consent		X				
Screening/Demographics	02	X				
Socio-Economics	04	X				
CTCC Unique ID	06	X				
Inclusion/Exclusion - HC	09	X				
Primary Diagnosis	12	X				
Medical History (General)	14	X				
Smoking and Alcohol Questionnaire	15	X				
Family History (PD)	16	X				
General Neurological Exam	18	X				
Vital Signs	20	X	X			X
Fasting Status	21	X	X			
MDS-UPDRS 3/Hoehn & Yahr	24	X[1]				
Montreal Cognitive Assessment (MoCA)	30	X				
REM Sleep Disorder Questionnaire	32	X				
DNA Sample	34	X				
Laboratory Procedures	36	X[2]	X[4]			
Saliva and Urine Samples	37		X			
Clinical Labs	38	X[3]				
Lumbar Puncture	40		X			
Investigator Signature	42	X	X	X		X
Visit Status	44	X	X	X		X
Adverse Event Log	46		X	X		
Concomitant Medication Log	50	X	X	X		X
Adverse Event Follow-up Log[7]	54			X		
Conclusion of Study Participation	52				X	

1 MDS-UPDRS part 3 motor only
2 10ml plasma between 1-3 hours after meds
3 CBC, platelet count, PT/PTT
4 Laboratory procedures include PAXgene™ and plasma EDTA purple top
5 Assessments at the discretion of the Investigator and to be recorded in source document
6 Adverse events assessed by phone 7 - 10 days following LP
7Any AE ongoing at the 7 to 10 day reporting telephone visit should be followed until resolution or stabilization, but not more than 30 days from lumbar puncture.